What is the recommended management, including post‑exposure prophylaxis regimen, HIV testing schedule, and hepatitis B prophylaxis, for a healthcare worker who sustained a percutaneous needle‑stick injury with a needle known to be contaminated with HIV (the needle passed through nitrile gloves)?

Management of Known HIV-Positive Needlestick Injury

Start HIV post-exposure prophylaxis (PEP) immediately—ideally within 1–2 hours—using bictegravir/emtricitabine/tenofovir alafenamide (one tablet daily for 28 days), and do not delay initiation while awaiting any test results. 1

Immediate Actions (Within Minutes to 1 Hour)

• Wash the puncture site thoroughly with soap and water without squeezing or applying pressure; caustic agents such as bleach should never be applied to the wound. 2, 3

• Report the incident to your supervisor within 1 hour and document the exact time of injury, needle type, depth of penetration, visible blood contamination, and the fact that the needle passed through nitrile gloves. 3

• Do not delay PEP initiation—even passing through a glove, a percutaneous injury from a known HIV-positive source warrants immediate prophylaxis regardless of the source patient's viral load or undetectable status. 1

HIV Post-Exposure Prophylaxis Regimen

• Preferred single-tablet regimen: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) 50mg/200mg/25mg—one tablet once daily for 28 days. 1

• Alternative regimen: Dolutegravir (DTG) 50mg once daily PLUS emtricitabine/tenofovir alafenamide (FTC/TAF) 200mg/25mg once daily for 28 days. 1

• Complete the full 28-day course—stopping early eliminates protection, even if subsequent information suggests lower risk. 1, 3

• If renal impairment is present, use tenofovir alafenamide (TAF) rather than tenofovir disoproxil fumarate (TDF); assess baseline creatinine clearance before starting any tenofovir-based regimen. 1

Baseline Testing for the Exposed Worker (Before Starting PEP)

• Perform a rapid or laboratory-based HIV antigen/antibody combination test to establish baseline HIV status before the first PEP dose. 1, 3

• Obtain hepatitis B serology (HBsAg, anti-HBs, anti-HBc) to determine immune status and guide hepatitis B prophylaxis. 3, 4

• Test for hepatitis C antibody (anti-HCV) and alanine aminotransferase (ALT) as baseline markers. 3, 4

• Assess baseline renal function (creatinine, eGFR) and liver function tests before initiating PEP. 3

• Offer pregnancy testing to women of childbearing age whose status is unknown, as this may influence drug selection. 4

Source Patient Testing (Within 1–2 Hours)

• Confirm the source patient's HIV status by reviewing medical records for documented HIV infection, viral load, CD4+ count, and current antiretroviral therapy. 2

• Test the source for hepatitis B surface antigen (HBsAg) and hepatitis C antibody (anti-HCV) to guide additional prophylaxis decisions. 3, 4

• Do not delay PEP while awaiting source testing—initiate prophylaxis immediately based on the known HIV-positive status. 1

Hepatitis B Prophylaxis

• If you are unvaccinated or incompletely vaccinated against hepatitis B and the source is HBsAg-positive or status unknown, administer hepatitis B immune globulin (HBIG) 0.06 mL/kg intramuscularly as soon as possible (ideally within 24 hours) and begin the hepatitis B vaccine series at a separate injection site. 3

• If you have documented hepatitis B immunity (anti-HBs ≥10 mIU/mL), no hepatitis B treatment is required regardless of source status. 3

• If you are a vaccine non-responder (anti-HBs <10 mIU/mL) and the source is HBsAg-positive, give HBIG 0.06 mL/kg immediately and a second dose in one month, or HBIG plus revaccination. 3

Hepatitis C Management

• No post-exposure prophylaxis exists for hepatitis C—early identification through baseline and serial testing is the only strategy. 3, 4

• The average transmission risk for hepatitis C after a needlestick from a confirmed positive source is approximately 1.8%, compared to 0.3% for HIV and up to 30% for hepatitis B (if HBeAg-positive). 3

HIV Follow-Up Testing Schedule

• Perform HIV antibody or antigen/antibody combination testing at baseline (before PEP), 4–6 weeks, and 12 weeks after exposure. 1

• If any acute illness develops during follow-up (fever, rash, lymphadenopathy, fatigue), perform immediate HIV testing as these may indicate acute retroviral syndrome. 3, 4

Hepatitis C Follow-Up Testing Schedule

• Obtain baseline anti-HCV antibody and ALT at the time of exposure. 4

• Repeat anti-HCV antibody and ALT testing at 4–6 months post-exposure. 3, 4

• If earlier diagnosis is desired, perform HCV RNA testing at 4–6 weeks post-exposure. 3, 4

• Confirm any repeatedly reactive anti-HCV enzyme immunoassay with supplemental testing (e.g., recombinant immunoblot assay). 4

Hepatitis B Follow-Up Testing

• If you received the hepatitis B vaccine series after exposure, test anti-HBs 1–2 months after the final vaccine dose to confirm protective immunity (≥10 mIU/mL). 3, 4

• If HBIG was administered, defer anti-HBs testing until 4–6 months after HBIG to avoid detecting passively transferred antibodies. 3

Monitoring During PEP

• Evaluate the exposed worker within 72 hours of starting PEP and monitor for drug toxicity with complete blood count, renal function (creatinine, eGFR), and hepatic function tests every 2 weeks during the 28-day course. 3

• Common side effects of PEP include nausea, fatigue, headache, and diarrhea—these should not prompt discontinuation unless severe, but warrant supportive management and adherence counseling. 5, 6

Precautions During Follow-Up Period

• You do not need to modify patient-care duties or take special precautions to prevent secondary transmission during the follow-up period after occupational exposure. 2, 3

• Use barrier protection during sexual activity and do not donate blood, plasma, organs, tissue, or semen until cleared by follow-up testing. 3

• Seek immediate medical evaluation for any acute illness during the follow-up period, as this may indicate acute HIV infection or drug toxicity. 3, 4

Expert Consultation

• For complex cases or questions about drug selection, contact the National PEPline at 888-448-4911 for 24/7 expert consultation, but do not delay PEP initiation while awaiting consultation. 1

Common Pitfalls to Avoid

• Never delay PEP beyond 72 hours—efficacy decreases dramatically after 24 hours, and PEP is generally not recommended if more than 72 hours have elapsed since exposure. 1, 3

• Do not stop PEP early based on reassuring information about the source patient's undetectable viral load—occupational exposures warrant the full 28-day course regardless of source viral suppression. 1

• Do not squeeze the wound or apply caustic agents such as bleach—these practices provide no benefit and may cause harm. 2, 3

• Do not skip the 4–6 week HIV test—this is the earliest time point for detecting acute infection if PEP fails. 1

• Ensure a system is in place to encourage return for all scheduled follow-up tests—inadequate follow-up is a common failure point in post-exposure management. 4